Status | Study |
Completed |
Study Name: Scleroderma ARFI Imaging of the Skin Condition: Scleroderma Date: 2013-11-26 Interventions: Device: ARFI-SVI Ultrasound Ultrasound imaging of arm and leg lasting approximately 5-10 minutes. Partic |
Terminated |
Study Name: Fractional Carbon Dioxide Laser Versus UVA 1 in Treatment of Localized Scleroderma Condition: Localized Scleroderma Date: 2013-09-05 Interventions: Device: Fractional carbon dioxide laser |
Recruiting |
Study Name: Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository Condition: Scleroderma, Localized Morphea Date: 2013-02-25 Interventions: Other: Morphea Other Names: Scleroderma, Localized Scleroderma |
Recruiting |
Study Name: Treatment Study Comparing UVA-1 Phototherapy Versus Placebo Treatment for Morphea Condition: Scleroderma, Localized Morphea Date: 2013-02-22 Interventions: Procedure: UVA-1 Phototherapy Procedure: P |
Completed |
Study Name: A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy Condition: Debilitating Fibrosing Skin Disorders (Localised Scleroderma, Eosinophilic Fasciitis) Date: 2009-07-09 Interventions: Drug: Rituximab Mabthera, Rituximab 1000 mg I.V. |
Completed |
Study Name: Treatment Study Comparing Medium or High Dose Uva-1 Treatment 3x/Week Versus Fluocinonide 0.05% Cream in the Treatment of Morphea. Condition: Symmetric Limited Morphea. Date: 2008-12-18 Interventions: Other: Medium Dose UVA-1 UVA-1 |
Completed |
Study Name: Efficacy and Safety of Imatinib in Scleroderma Condition: Scleroderma, Localized Scleroderma, Systemic Date: 2007-05-29 Interventions: Drug: imatinib mesylate 6 month treatment with 400mg/day (per os) |
Withdrawn |
Study Name: Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study Condition: Morphea Date: 2005-09-28 Interventions: Drug: imiquimod 5% cream (Aldara) |
Completed |
Study Name: Imiquimod in Children With Plaque Morphea Condition: Scleroderma, Localized Date: 2005-09-02 Interventions: Drug: Imiquimod 5% cream Treatment will last for 36 weeks. Patients will be instructed to apply Imiquimo |
Completed |
Study Name: Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix Condition: Keloid Scleroderma, Localized Date: 2005-08-09 Interventions: Procedure: UVB Irradiation A dose of up to 320 mJ/cm2 from a UVB irradiation device will be administered |